# ANKUR DRUGS AND PHARMA LIMITED

Registered Office: C-306, Crystal Plaza, Andheri Link Road, Andheri (West), Mumbai- 400 053

## UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2011

(INR in lacs)

| Sr. No. | Particulars | Quarter ended on 31.12.2011 (Un-audited) | Quarter ended on 31.12.2010 (Un-audited) | Nine months ended on 31.12.2011 (Un-audited) | Nine months ended on 31.12.2010 (Un-audited) | Year ended on 31.03.2011 (Audited) |
|---|---|---|---|---|---|---|
| 1. | a) Net Sales/Income from Operations | 3,842.36 | 15,018.52 | 11,492.43 | 70,275.81 | 82,399.74 |
| | b) Other Operating Income | 7.55 | 15.95 | 21.99 | 45.23 | 55.93 |
| | **Total Income** | **3,849.91** | **15,034.47** | **11,514.42** | **70,321.04** | **82,455.67** |
| 2. | **Total Expenditure** | | | | | |
| | a) (Inc.)/Dec. in stock in trade and work in progress | 402.08 | 49.12 | 1,731.09 | (668.49) | 3,961.96 |
| | b) Consumption of raw materials | 2,497.47 | 10,662.78 | 6,355.55 | 50,971.80 | 57,679.92 |
| | c) Employee cost | 714.45 | 858.31 | 2,237.39 | 2,133.83 | 2,865.41 |
| | d) Depreciation | 1,511.90 | 1,925.13 | 4,579.72 | 3,894.22 | 6,079.70 |
| | e) Other Expenditure | 978.36 | 1,276.61 | 3,218.59 | 3,846.33 | 4,643.52 |
| | f) **Total** | **6,104.26** | **14,771.95** | **18,122.34** | **60,177.69** | **75,230.51** |
| 3. | **PROFIT FROM OPERATIONS BEFORE OTHER INCOME, INTEREST AND EXCEPTIONAL ITEMS (1-2)** | **(2,254.35)** | **262.52** | **(6,607.92)** | **10,143.35** | **7,225.16** |
| 4. | Other Income | 1.03 | 5.68 | 5.43 | 16.67 | 122.33 |
| 5. | **PROFIT BEFORE INTEREST AND EXCEPTIONAL ITEMS (3+4)** | **(2,253.32)** | **268.20** | **(6,602.49)** | **10,160.02** | **7,347.49** |
| 6. | a) Interest and other financial charges (net of reversal of interst for previous year) | 1,349.78 | 2,522.64 | 3,051.15 | 7,603.75 | 10,926.97 |
| | b) Provision for premium on redemption of FCCBs | 59.36 | 227.45 | 548.86 | 679.88 | 1,097.07 |
| 7. | **PROFIT/(LOSS) AFTER INTEREST BUT BEFORE EXEPTIONAL ITEMS (5-6)** | **(3,662.46)** | **(2,481.89)** | **(10,202.50)** | **1,876.39** | **(4,676.55)** |
| 8. | Exceptional Items | - | - | - | (76.01) | - |
| 9. | **PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7+8)** | **(3,662.46)** | **(2,481.89)** | **(10,202.50)** | **1,952.40** | **(4,676.55)** |
| 10. | **Tax Expense** | | | | | |
| | a) Income Tax (including for earlier years) | - | (473.00) | - | 390.00 | 141.07 |
| | b) Deferred Tax | - | - | - | - | 2,063.18 |
| 11. | **NET PROFIT/LOSS FROM ORDINARY ACTIVITIES AFTER TAX (9-10)** | **(3,662.46)** | **(2,008.89)** | **(10,202.50)** | **1,562.40** | **(6,880.80)** |
| 12. | **Extra Ordinary Item (net of tax expense )** | - | - | - | - | - |
| 13. | **NET PROFIT/LOSS FOR THE PERIOD (11-12)** | **(3,662.46)** | **(2,008.89)** | **(10,202.50)** | **1,562.40** | **(6,880.80)** |
| 14. | Paid-up Equity Share Capital | 1,934.16 | 1,934.16 | 1,934.16 | 1,934.16 | 1,934.16 |
| 15. | Reserves & Surplus (Excluding Revaluation Reserve) | | | | | 26,913.23 |
| 16. | Earning per share (Rs.) (Basic/Diluted) | | | | | |
| | -Basic | (18.94) | (10.39) | (36.80) | 8.08 | (35.58) |
| | -Diluted | (14.45) | (8.07) | (32.31) | 6.27 | (23.20) |
| 17. | Public Shareholdings | | | | | |
| | -Number of Shares | 15934565 | 14884059 | 15934565 | 14884059 | 14601709 |
| | -Percentage of Shareholding (%) | 82.38 | 76.95 | 82.38 | 76.95 | 75.49 |

| | | | | | | |
|---|---|---|---|---|---|---|
| 18. | Promoters and promoter group shareholding** | | | | | |
| | a) Pledged/Encumbered | | | | | |
| | -Number of Shares | 2441000 | 3473500 | 2441000 | 3473500 | 3773000 |
| | -Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 71.65 | 77.92 | 71.65 | 77.92 | 79.60 |
| | -Percentage of shares (as a % of the total share capital of the Company) | 12.62 | 17.96 | 12.62 | 17.96 | 19.51 |
| | b) Non-encumbered | | | | | |
| | -Number of Shares | 966025 | 984031 | 966025 | 984031 | 966881 |
| | -Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 28.35 | 22.08 | 28.35 | 22.08 | 20.40 |
| | -Percentage of shares (as a % of the total share capital of the company) | 4.99 | 5.09 | 4.99 | 5.09 | 5.00 |

NOTES:

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors of the company in their meeting held on 1st February, 2012.
2. Investor complaints received and disposed off during quarter ended December 31, 2011:

| | |
|---|---|
| Complaints pending at the beginning of the quarter | NIL |
| Complaints received during the quarter | 2 |
| Disposal of complaints | 2 |
| Complaints lying unresolved at the end of the quarter | NIL |

3. As the company operates in a single business segment viz: "Pharmaceuticals Formulations", in the context of Accounting Standard 17 disclosure of segment information is not applicable.
4. As per company's policy provision for exchange difference on foreign currency loans, deferred tax liability and miscellanous expenditure will be written off at the end of the financial year only.
5. The Board has considered the proposal to increase Authorised Share Capital of the company from Rs.28 Crs to Rs.156 Crs in pursuance of Section 16, 31, 94 of the Companies Act, 1956 and the subsequent Alteration of Memorandum and Articles of Association with the consent of the Members.
6. The Board has considered the proposal to reclassify the Share Capital in accordance with the increase in Authorised Capital from Rs.28 Crs to Rs.156 Crs in pursuance of Article 4 of Articles of Association of the Company.
7. The Board has considered the proposal to alter Articles of Association by insertion of Article 8A for power to issue Optionally Convertible Cumulative Redeemable Preference Shares in the capital of the Company.
8. The Board has considered the proposal to issue 0.001% Optionally Convertible Cumulative Redeemable Preference Shares of the face value of Rs.100/- on a preferential basis to the CDR Lenders of Rs.132,19,79,000/-, in pursuance to the CDR Scheme as approved by the CDR EG
9. The Board has resolved to conduct Postal Ballot for the Sr. No(s). 5, 6, 7 and 8 above and the Calendar of Events has been approved. The Board has further resolved to appoint Ms. Rachana Kamat, Practicing Company Secretary as the scrutinizer in this respect.

For **ANKUR DRUGS AND PHARMA LIMITED**

Sd/-
**PURNANDU JAIN**
Chairman and Managing Director

Place : Mumbai.
Dated: 1st February, 2012